Calamos Supports Greece

Leqembi

Second Alzheimer’s Drug to Slow Disease’s Progression

After Leqembi, another drug that might hit the market by the end of this year for Alzheimer's disease is Donanemab, and it's being developed by Eli Lilly. In a recent study, donanemab showed promise in slowing the progression of...

FDA Approves the Leqembi Drug that Slows Alzheimer’s Progress

The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen and Eisai Alzheimer’s treatment Leqembi. Leqembi, also known as lecanemab, is the first drug shown to slow the progress of the disease, rather than just treating...